NYLIM
HAE icon

New York Life Investment Management’s Haemonetics HAE Stock Holding History

New York Life Investment Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,368
Closed -$373K – 1056
2024
Q1 		$373K Buy
4,368
+193
+5% +$15.1K ﹤0.01% 924
2023
Q4 		$357K Sell
4,175
-127
-3% -$11K ﹤0.01% 1096
2023
Q3 		$385K Sell
4,302
-678
-14% -$60.5K ﹤0.01% 921
2023
Q2 		$424K Sell
4,980
-962
-16% -$81.3K ﹤0.01% 905
2023
Q1 		$492K Buy
+5,942
New +$481K 0.01% 718

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York Life Investment Management's HAE Position: Q2 2024 in Review

New York Life Investment Management sold out of Haemonetics (HAE) in Q2 2024, closing a stake of 4,368 shares — an estimated $373K sold.

New York Life Investment Management first reported a position in HAE in Q1 2023 and held it in 5 quarters. The position peaked at $492K in Q1 2023. 317 funds tracked by Wall St. Rank hold HAE as of Q2 2024.

  • New York Life Investment Management reported no remaining Haemonetics position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 4,368 Haemonetics shares in Q2 2024, an estimated $373K.
  • New York Life Investment Management first reported a position in Haemonetics in Q1 2023 and held it in 5 quarters.
  • New York Life Investment Management's Haemonetics position peaked at $492K in Q1 2023.
  • 317 funds tracked by Wall St. Rank held Haemonetics as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.